Go Pro

Insider Selling: Billiontoone (NASDAQ:BLLN) SVP Sells $150,959.76 in Stock

Billiontoone logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Insider sale: SVP Bosch John Roderick Ten sold 1,416 Billiontoone shares for approximately $150,960 at an average price of $106.61 under a pre-arranged Rule 10b5-1 plan. He continues to own 23,635 shares worth roughly $2.52 million.
  • Stock performance: BLLN traded at $114.42, with a $5.40 billion market capitalization and a P/E ratio of 163.46. The stock has ranged from $61.96 to $150.44 over the past year.
  • Analyst outlook: Billiontoone has an average “Hold” rating and a consensus price target of $125.88, with seven Buy, two Hold, and two Sell ratings. The company met quarterly EPS expectations at $0.15 and reported $109.45 million in revenue.
  • MarketBeat previews top five stocks to own in October.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) SVP Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $106.61, for a total transaction of $150,959.76. Following the completion of the transaction, the senior vice president directly owned 23,635 shares in the company, valued at approximately $2,519,727.35. This represents a 5.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

  • On Wednesday, September 9th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The stock was sold at an average price of $97.54, for a total transaction of $138,116.64.
  • On Tuesday, August 25th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The shares were sold at an average price of $100.00, for a total transaction of $141,700.00.
  • On Monday, August 10th, Bosch John Roderick Ten sold 1,417 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total value of $131,582.62.
  • On Monday, June 29th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $120.00, for a total value of $169,920.00.

Billiontoone Stock Performance

BLLN traded down $1.65 during midday trading on Wednesday, reaching $114.42. The company's stock had a trading volume of 397,672 shares, compared to its average volume of 550,296. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17. The company has a fifty day simple moving average of $109.25 and a 200 day simple moving average of $97.49. The stock has a market cap of $5.40 billion and a P/E ratio of 163.46. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $150.44.

Billiontoone (NASDAQ:BLLN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting analysts' consensus estimates of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%.The company had revenue of $109.45 million during the quarter. Research analysts expect that Billiontoone, Inc. will post 0.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BLLN shares. Canaccord Genuity Group assumed coverage on shares of Billiontoone in a report on Wednesday, September 2nd. They issued a "buy" rating and a $120.00 price target for the company. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Billiontoone in a research report on Friday. BTIG Research reduced their target price on shares of Billiontoone from $142.00 to $130.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Guggenheim started coverage on Billiontoone in a research report on Monday, June 29th. They set a "buy" rating and a $125.00 target price on the stock. Finally, Wall Street Zen lowered Billiontoone from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Billiontoone presently has an average rating of "Hold" and an average price target of $125.88.

Check Out Our Latest Research Report on BLLN

Institutional Trading of Billiontoone

Several institutional investors have recently made changes to their positions in BLLN. Adams Street Partners LLC acquired a new position in Billiontoone in the fourth quarter worth about $140,063,000. Wasatch Advisors LP boosted its holdings in Billiontoone by 40.2% during the second quarter. Wasatch Advisors LP now owns 518,084 shares of the company's stock valued at $62,160,000 after purchasing an additional 148,446 shares in the last quarter. Emerald Advisers LLC grew its stake in shares of Billiontoone by 26.8% in the 1st quarter. Emerald Advisers LLC now owns 239,562 shares of the company's stock valued at $18,911,000 after purchasing an additional 50,613 shares during the period. Capital International Investors bought a new stake in shares of Billiontoone in the 4th quarter valued at approximately $14,568,000. Finally, Emerald Mutual Fund Advisers Trust raised its holdings in shares of Billiontoone by 11.9% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company's stock worth $10,436,000 after buying an additional 14,072 shares in the last quarter.

About Billiontoone

(Get Free Report)

BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company's technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.

The company's primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.

Featured Articles

Insider Buying and Selling by Quarter for Billiontoone (NASDAQ:BLLN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Billiontoone Right Now?

Before you consider Billiontoone, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Billiontoone wasn't on the list.

While Billiontoone currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines